Charles River Laboratories International Inc
CRL: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$747.00 | Vdrnbq | Dtmxlvfjl |
Charles River Reports Strong Outlook for 2022; Lifting FVE to $260
Business Strategy and Outlook
Animal research models have been the foundation of Charles River's business since 1947, and the company has expanded to provide solutions encompassing research models and related services, drug discovery, preclinical testing, and manufacturing support. It services nearly all top and mid-tier biopharma players.